| Names | |
|---|---|
| IUPAC name 1-[(3,4-dihydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol | |
| Other names Norlaudanosoline; Tetrahydroxypapaveroline | |
| Identifiers | |
3D model (JSmol) | |
| 313061 | |
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.158.898 |
| EC Number |
|
| KEGG | |
PubChem CID | |
| UNII | |
CompTox Dashboard (EPA) | |
| |
| |
| Properties | |
| C16H17NO4 | |
| Molar mass | 287.315 g·mol−1 |
| Hazards | |
| GHS labelling: | |
| | |
| Warning | |
| H302 | |
| P264, P270, P301+P317, P330, P501 | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
Tetrahydropapaveroline, also known as norlaudanosoline, is a tetrahydroisoquinoline alkaloid. It is also classified as a benzylisoquinoline alkaloids. [1]
Tetrahydropapaveroline is relevant to brain pathologies. [2]
It can be formed in trace amounts in the brain by a condensation reaction of dopamine and dopaldehyde (a metabolite of dopamine). [2] [3]
It inhibits dopamine uptake within the cerebral cortex. [4]